文献速递间质性肺疾病

肺结节病的发病机制及其治疗启示

The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment.
PubMed 文献 · Chest · 2017-12-07

本综述聚焦胸部结节病中最常见的肺结节病,梳理了结节病抗原性质、血清淀粉样蛋白A等宿主因素、适应性T细胞谱及肉芽肿性炎症维持机制的最新进展,并探讨固有免疫作用、免疫细胞耗竭意义及肺纤维化机制,最后反思免疫抑制治疗时机与非药物管理策略及新靶点。

要点

  • 肺结节病与孤立性胸部淋巴结病不同,患病率和长期结局更差。
  • 持续性疾病活动常见,可导致肺纤维化,需关注疾病进展。
  • 固有免疫、血清淀粉样蛋白A及T细胞耗竭可能参与发病与纤维化。

核心结论

  • 肺结节病发病机制可能与其他结节病表现不同,涉及抗原、固有免疫、适应性T细胞及肉芽肿维持机制。
  • 免疫抑制治疗时机需结合疾病活动性与纤维化风险,非药物管理及新靶点值得关注。

研究设计与样本

  • 综述,聚焦肺结节病发病机制及治疗启示。

主要发现

  • 肺结节病炎症浸润可消退,但持续疾病活动常见并可导致肺纤维化。
  • 血清淀粉样蛋白A及其他宿主因素参与固有免疫改变。
  • 肺部适应性T细胞谱受多种因素影响,与肉芽肿性炎症维持相关。
  • 固有免疫在发病中的作用、免疫细胞耗竭的意义及肺纤维化机制是待解答问题。

临床怎么用

  • 临床需区分孤立性胸部淋巴结病与肺实质受累,后者疾病负担更重。
  • 对持续疾病活动者应评估肺纤维化风险。
  • 免疫抑制治疗需权衡时机,非药物管理策略可纳入综合管理。

局限性

  • 综述未提供具体研究数据或样本量。
  • 发病机制及治疗靶点多为待验证的假设或新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thoracic sarcoidosis is the most common form of sarcoidosis, encompassing a heterogeneous group of patients with a wide range of clinical features and associated outcomes. The distinction between isolated thoracic lymphadenopathy and pulmonary involvement matters. Morbidity is often higher, and long-term outcomes are worse for the latter. Although inflammatory infiltrates in pulmonary sarcoidosis may resolve, persistent disease activity is common and can result in lung fibrosis. Given the distinct clinical features and natural history of pulmonary sarcoidosis, its pathogenesis may differ in important ways from other sarcoidosis manifestations. This review highlights recent advances in the pathogenesis of pulmonary sarcoidosis, including the nature of the sarcoidosis antigen, the role of serum amyloid A and other host factors that contribute to alterations in innate immunity, factors that shape adaptive T-cell profiles in the lung, and how these mechanisms influence the maintenance of granulomatous inflammation in sarcoidosis. We discuss questions raised by recent findings, including the role of innate immunity in the pathogenesis, the meaning of immune cell exhaustion, and mechanisms that may contribute to lung fibrosis in sarcoidosis. We conclude with a reflection on when and how immunosuppressive therapies may be helpful for pulmonary sarcoidosis, a consideration of nonpharmacologic management strategies, and a survey of potential novel therapeutic targets for this vexing disease.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Patterson KC, Chen ES. The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment. Chest. 2017. PMID: 29224832. doi:10.1016/j.chest.2017.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。